# EDGAR Filing Document

**Accession Number:** 0001885827
**File Stem:** 9999999995-23-000763
**Filing Date:** 2023-3
**Character Count:** 1361
**Document Hash:** ce6fd474405951e99b2149034049e017
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-23-000763.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 9999999995-23-000763

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virax Biolabs Group Ltd
- **CENTRAL INDEX KEY:** 0001885827
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270734
- **FILM NUMBER:** 23782895

**BUSINESS ADDRESS:**
- **STREET 1:** 30 BROADWICK STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1F 8LX
- **BUSINESS PHONE:** 44 020 7788 7414

**MAIL ADDRESS:**
- **STREET 1:** 30 BROADWICK STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1F 8LX

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virax Biolabs (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20210930

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** March 30, 2023

**Time:** 17:00:00

**Form Type:** F-1

---

**CIK:** 0001885827

**Company Name:** Virax Biolabs Group Ltd

**File Number:** 333-270734